Phase 2b Study Findings for an Oral IL-23 Blocker in Psoriasis are Encouraged.

Published Date: 08 Jul 2023

In the FRONTIER 1 study, an investigational IL-23R antagonist significantly outperformed placebo at week 16 in terms of effectiveness in patients with moderate to severe psoriasis across all doses.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Stem Cell Selection Unneeded for SSc Transplant Therapy?

2.

Lung Transplant for Lung Cancer: Promising, in Rare Cases

3.

Rural-urban disparities seen in cervical cancer

4.

Obesity linked to subsequent neoplasms in childhood cancer survivors

5.

New policy review highlights the importance of health-related quality of life in advanced cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot